Outcome of Disseminated Intravascular Coagulation in Relation to the Score when Treatment was Begun

Summary

We examined 395 patients with disseminated intravascular coagulation (DIC) divided into two groups: non-leukemic and leukemic. In 58% of the patients as a whole, treatment of DIC resulted in complete or partial remission, while exacerbation and death occurred in 31%. The efficacy of DIC treatment in the non-leukemic group was less than that in the leukemic group, indicating that the outcome of DIC depended, in part, on the underlying disease. We examined hemostatic indicators in relation to DIC score: prothrombin time (PT) ratio, FDP, platelet count, and fibrinogen levels were found to be important indicators for the diagnosis of DIC, but not for Pre-DIC. Plasma levels of fibrin-D-dimer, thrombin-antithrombin complex (TAT), and plasmin- plasmin inhibitor complex (PPIC) were significantly increased in pre-DIC. The efficacy of treatment in relation to the DIC score when the treatment was begun showed that greater efficacy was achieved in pre-DIC than in DIC patients. The outcome was poorer with increasing DIC score, suggesting that early diagnosis and early treatment are important. On examining the relationship between outcome and hemostatic indicators, we found that the PT ratio and the levels of antithrombin, plasminogen, PPIC, the PPIC/TAT ratio, and thrombomodulin were related to outcome, suggesting that very high consumption of blood coagulation factors, liver dysfunction, hypofibrinolysis, or organ failure caused a poor outcome. Although the outcome in DIC patients may not depend substantially on plasma levels of TAT and fibrin-D- dimer, we can use these indicators to treat DIC patients at an early stage.

• References

• 1 Bick RL. Disseminated intravascular coagulation and related syndromes: A clinical review. Semi Thromb Hemost 1988; 14: 299-338
• 2 Muller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semi Thromb Hemost 1989; 15: 58-98
• 3 Ohno H, Kambayashi J, Chang SW, Kosaki FoyG. (ethyl p-(6-guanidino- hexanoxyloxy) benzoate] methaneslfonate as a serine protease inhibitor: II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1980; 24: 455-452
• 4 Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC): A multicentric cooperative double-blind trial in comparison with heparin. Thromb Res 1993; 72: 475-500
• 5 Larcan A, Lambert H, Gerard A. Treatment of consumption coagulopathies. Masson Publishing; 1987. pp 165-181
• 6 Pelzer H, Schwarz A, Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with an enyzme-linked immunosorbent assay. Thromb Haemost 1987; 59: 101-106
• 7 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Hemostasis and Thrombosis eds Coller BSPhiladelphia, WB Saunders. 1989; 9 pp 087-115
• 8 Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
• 9 Bredbacka S, Blomback M, Wiman B. Soluble fibrin: A predictor for the development and outcome of multiple organ failure. Am J Hematol 1944; 46: 289-294
• 10 Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Osterman H, van de Loo J. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complexes in patients with angina pectoris: relations to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70: 550-553
• 11 Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated vascular coagulation. Am J Hematol 1992; 39: 20-24
• 12 Jansson J-H, Jansson B, Boman K, Nilsson TK. Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Int Med 1991; 229: 309-316
• 13 Harpel PC. α-2 plasmin inhibitor and α-2 macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay J Clin Invest 1981; 68: 46-55
• 14 Kobayashi N, Maegawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1987; 49: 265-275
• 15 Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi A, Mori Y, Deguchi K, Shirakawa S, Suzuki K. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1994; 43: 190-194
• 16 Wada H, Tomeoku M, Deguchi A, Suzuki H, Mori Y, Ito M, Deguchi K, Shirakawa S. Anticoagulant activity in cell homogenate of adult T cell leukemia. Thromb Haemost 1988; 59: 197-201
• 17 Al-Mondhiry H. Disseminated intravascular coagulation. Experience in a major cancer center Thromb Diath Haemorrh 1975; 31: 181-193
• 18 Fujii S, Muramatsu M. Inhibitory effect of 4-guanidino acid esters on trypsin, plasmin, plasma kallikrein and thrombin. Biochim Biophys Acta 1972; 268: 221-224
• 19 Okajima K, Imamura H, Koga S, Inoue M, Takatsuki K, Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol 1990; 33: 277-278
• 20 Gralnick HR. Cancer cell procoagulant activity. Malignancy and hemostatic system. Donati MB. ed New York: Raven Press; 1981: 57-61
• 21 Wada H, Kumeda Y, Ogasawara Z, Ohiwa M, Kaneko T, Tamaki S, Ohno T, Kageyama S, Kobayashi T, Deguchi K, Shirakawa S. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol 1993; 42: 166-170
• 22 Takahashi H, Tatewaki W, Wada K, Hanano M, Shibata A, Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various disorders. Am J Hematol 1990; 33: 90-95
• 23 Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi K, Shirakawa S, Hayashi T, Suzuki K. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Hematol 1993; 44: 85-88
• 24 Kruithof EK O, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and 2 in various disease states. Thromb Haemost 1988; 59: 07-12
• 25 Esmon CT. The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746
• 26 Uchiyama H, Hiraishi S, Ohtani H, Ishii H, Kazama M. Plasma thrombomodulin is originated by damage of endothelial cell. Throm Haemost 1989; 62: 276-282
• 27 Giddings JC, Coles P, Williams BD. Comparison of thrombomodulin and von Willebrand factor antigen in human plasma in various disease. Thromb Haemost 1989; 62: 233-239